<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284205</url>
  </required_header>
  <id_info>
    <org_study_id>EN3348-302</org_study_id>
    <nct_id>NCT01284205</nct_id>
  </id_info>
  <brief_title>First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC</brief_title>
  <official_title>Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioniche Life Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioniche Life Sciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as
      first line treatment in patients with non-muscle invasive bladder cancer that are at high
      risk for recurrence or progression.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This indication is not being pursued at this point in time.
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of disease-free survival (time to recurrence, progression or death) in all patients</measure>
    <time_frame>Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patients who due to study drug-related AEs experience 2 consecutive treatment delays or discontinue due to drug related AEs</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival rate at 2 years</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity, and nature of drug-related AEs</measure>
    <time_frame>Baseline through 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival (time to progression or death) in all patients</measure>
    <time_frame>Baseline, Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity, and nature of drug-related SAEs</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment delays and their reason</measure>
    <time_frame>Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity and nature of all AEs</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment discontinuations and their reason</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Survival (time to death from any cause) in all patients</measure>
    <time_frame>Baseline through month 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>MCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical Administration of Mycobacterial Cell-Wall DNA Complex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravesical Administration of Bacillus Calmette-Guerin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mycobacterial Cell-Wall DNA Complex</intervention_name>
    <description>8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.</description>
    <arm_group_label>MCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacillus Calmette-Guerin</intervention_name>
    <description>mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.</description>
    <arm_group_label>BCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed urothelial carcinoma of the bladder (high grade Ta or T1
             papillary lesions, CIS)

          -  histologically confirmed diagnosis within 42 days of study treatment

          -  life expectancy of greater than 5 years

          -  ECOG performance status of 2 or less

          -  absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra
             within 12 months from start of study treatment

        Exclusion Criteria:

          -  current or previous history of muscle invasive bladder tumors (&gt;T2)

          -  current or previous history of lymph node and/or distant metastases from bladder
             cancer

          -  current evidence of squamous cell carcinoma, adenocarcinoma or undifferentiated
             carcinoma of the bladder

          -  current systemic cancer therapy

          -  previous immunotherapy for bladder cancer

          -  previous intravesical chemotherapy treatment

          -  contraindication to use BCG of known tolerance to BCG

          -  history of malignancy of any organ system within the past 5 years (with the exception
             of basal cell or squamous cell carcinoma, stage T1 prostate cancer, carcinoma in situ
             of the cervix, colon polyps)

          -  patients who cannot tolerate intravesical administration or intravesical surgical
             manipulation (cystoscopy or biopsy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <name_title>Director of CRND</name_title>
    <organization>Endo Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>non-muscle invasive bladder cancer</keyword>
  <keyword>superficial bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

